GlobeNewswire

B-Temia and Wistron Join Forces to Launch Keeogo(TM) in Asia

Dela

B-Temia and Wistron form B-Temia Asia to bring Keeogo(TM) to the Asian Market

QUEBEC CITY, June  07, 2018  (GLOBE NEWSWIRE) -- B-Temia Inc., a Canadian biorobotics technology company and market leader in human mobility, entered into a joint venture agreement with Wistron Corporation to launch its Keeogo(TM) Dermoskeleton(TM) technology in Asia. Wistron is one of the world's largest Original Design Manufacturer (ODM), with more than $34 billion CAD sales, and now a major shareholder of B-Temia since June 2017. Wistron and B-Temia form B-Temia Asia for the marketing of Keeogo(TM) in several Asian countries such as China, Japan and Hong Kong. Headquartered in Singapore, B-Temia Asia will benefit from a significant investment from Wistron in exchange for marketing rights for Keeogo(TM) products in Asia.

"B-Temia Asia represents the realization of our business plan and our mission to help people regain their independence through mobility. B-Temia is now expanding around the world, which is another demonstration of the real value of our technology and the need to bring modern and revolutionary solutions to the many people living with mobility limitations. In addition, we are excited to expand and strengthen our partnership with Wistron. Over the last year, both organizations have effectively proven their ability to work together for manufacturing transfer to Asia. This joint venture is the next logical step for Wistron, which became a major shareholder of our company in 2017", said Stéphane Bédard, CEO of B-Temia. "This international expansion is a very exciting time for our shareholders said Mr. Bédard.

"Wistron is advancing the development and application of medical technologies to help people with mobility challenges and we are very excited to increase our partnership with B-Temia and to work closely together to develop the human mobility market in Asia. This partnership directly supports our goal of improving people's lives through technology", said Donald Hwang, Chief Technology Officer (CTO) of Wistron Corporation.

About Keeogo(TM) Dermoskeleton(TM)

Keeogo(TM) is a motorized walking assistive device developed by B-Temia. Keeogo(TM), short for "Keep on Going", has been used by people suffering from degenerative diseases such as osteoarthritis of the knee or hip, multiple sclerosis, Parkinson's disease, stroke, incomplete spinal cord injury and other mobility-limiting diseases. Used as a rehabilitation equipment or as a home assistive device to help with daily activities, Keeogo(TM) is approved by Health Canada and is commercially available in Canada for purchase or rental. For more information, please visit: www.keeogo.com.

About B-Temia

Founded in 2010, B-Temia Inc. is an innovative Canadian medical device manufacturer that develops and markets leading edge products for the growing market of human augmentation systems. B-Temia operates through two wholly owned subsidiaries, B-Temia Inc. and B-Temia USA Inc., in the medical, industrial and military fields. B-Temia has a patented technology called Dermoskeleton(TM) that restores, maintains or enhances user mobility. For more information, please visit: www.b-temia.com.

About Wistron

Wistron Corporation is one of the world's largest companies to produce servers and storage devices for cloud computing and data centers, desktop and laptop computers, smart phones, industrial devices and control units, medical devices, Artificial Intelligence and Big Data Analysis. Wistron's full line of engineering teams enables Wistron's customers to outsource all or part of their product development and manufacturing tasks to focus on their core competencies and further develop their intellectual properties. Wistron manufactures medical products for customers in the medical industry at two ISO 13485-certified factories in Taiwan's Hsinchu Science Park and in Chongqing, China. For more information, please visit: www.wistron.com.

Information

Source:
B-Temia Inc.
4780, St-Félix Street, Suite 105
St-Augustin (Québec) G3A 2J9
www.b-temia.com | www.keeogo.com
Phone: (418) 653-1010
E-mail: info@b-temia.com

 
Media:
Pamela Borges
VP Market Access & External Affairs
Phone: (418) 653-1010, ext. 223
E-mail: pamela.borges@b-temia.com





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: B-Temia Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

ICONOVO TECKNAR AVTAL MED MCMASTER UNIVERSITY AVSEENDE UTVECKLING AV VACCIN MOT TUBERKULOS15.10.2018 09:00Pressmeddelande

Det innovativa, Lundabaserade medicinteknikföretaget Iconovo AB (publ) meddelar i dag att bolaget har skrivit samarbetsavtal med McMaster University i Kanada. Avtalet avser utveckling av en torrpulverberedning av inhalerbart vaccin mot tuberkulos som ska användas i Iconovos unika engångsinhalator ICOone. Iconovo kommer att ingå i ett tvärvetenskapligt forsknings- och utvecklingsprojekt som syftar till att ta fram nästa generations virusbaserade vaccin i pulverform som är stabilt i rumstemperatur. Att kunna transportera vaccin utan krav på kylförvaring är en förutsättning för att snabbt och effektivt nå ut till de behövande. I det projekt som nu påbörjas kommer Iconovos unika engångsinhalator ICOone att användas som testplattform för att underlätta en framtida kommersialisering och storskalig tillverkning. Projektet beräknas pågå i tre år och finansieras bland annat av den kanadensiska staten (CIHR/NSERC). Tuberkulos förekommer i hela världen och är en av de tio vanligaste dödsorsakerna

Stillfront Group AB: Babil Games lanserar Arab Gamers' League4.10.2018 10:02Pressmeddelande

PRESSMEDDELANDE 4 oktober 2018 Babil Games, en del av Stillfront Group, ökar affärstillväxten och lanserar Arab Gamers' League, AGL Babil Games, ett dotterbolag till Stillfront Group, inleder partnerskap med kreativa byrån Grape Creations i Dubai och lanserar Arab Gamers' League (AGL), en ny studio som fokuserar på att lansera så kallade 'social casual games' till MENA-regionen. Babil Games kontrollerar 51% av AGL och Grape Creations övriga 49%. Babil Games är ansvarig för verksamheten och sourcing av spel medan Grape Creations ansvarar för marknadsföring och distribution. "Vi är mycket glada över vårt inledda partnerskap med Grape Creations gällande lanseringen av Arab Gamers' League. AGLs fokus är att lansera nästa generations 'social casual games' till MENA-regionen", säger MJ Fahmi, VD för Babil Games. Babil Games kommer att fortsätta att fokusera på MMO-strategispel. Antalet anställda i Babil Games har fördubblats under det senaste året och studion kommer att flytta till ett nytt

Stillfront Group AB: Babil Games launches Arab Gamers' League4.10.2018 10:02Pressmeddelande

PRESS RELEASE 4 October 2018 Babil Games, part of the Stillfront Group, accelerates business growth and launches Arab Gamers' League, AGL Babil Games, a subsidiary of Stillfront Group, is partnering with Dubai based creative agency Grape Creations to launch Arab Gamers' League (AGL), a new studio focused on bringing social casual games to the MENA-region. Babil Games controls 51% of AGL and Grape Creations the other 49%. Babil Games is head of the operations and the sourcing of the games while Grape Creations is responsible for marketing and distribution. "We are pleased to have Grape Creations as our partner for the launch of Arab Gamers League. In AGL we will focus on bringing the next generation of social casual games to the MENA region", says MJ Fahmi, CEO of Babil Games. Babil Games will continue to focus on strategy MMO games. The number of employees in Babil Games has doubled during the year and the studio will relocate to a new larger office in Amman, Jordan. "The expansion is

Hoylu AB: UNITED STATES AIR FORCE SELECTS HOYLU FOR COLLABORATION AND INNOVATION SOLUTIONS28.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 28, 2018 - Hoylu, a leading enterprise collaboration company announced today that the United States Air Force has selected Hoylu Software and multiple large format HoyluWall systems as a digital workspace tool for workspace innovation and collaboration. Hoylu software will be used at multiple sites to create joined environments within the division. The order will be delivered in Q4 2018 and represents a deal value of SEK 3,670,000 in product and software revenue. The Air Force will use the system for training and education purposes, with the ability to connect users together and collaborate in real-time. The order represents a growing market for Hoylu software and services within the government sector. It is expected that Hoylu's solutions will continue to expand within this industry as innovative collaboration solutions are in demand. Hoylu's solutions and software offer new and exciting ways to learn and collaborate smarter, faster and more efficiently. Creat

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum